Computed tomography imaging assessment of postexternal beam radiation changes of the liver.
暂无分享,去创建一个
[1] B. Siewert,et al. CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors , 2015, Gastroenterology research and practice.
[2] C. Bassi,et al. Prognostication and response assessment in liver and pancreatic tumors: The new imaging. , 2015, World journal of gastroenterology.
[3] A. Kramar,et al. Lobulated enhancement evaluation in the follow-up of liver metastases treated by stereotactic body radiation therapy. , 2015, International journal of radiation oncology, biology, physics.
[4] L. Dawson,et al. Localized and systemic approaches to treating hepatocellular carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. N. Kim,et al. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment , 2015, Expert review of gastroenterology & hepatology.
[6] Zhe Chen,et al. Motion management in gastrointestinal cancers. , 2014, Journal of gastrointestinal oncology.
[7] The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation? , 2014, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.
[8] S. Park,et al. Stereotactic Body Radiotherapy-Induced Arterial Hypervascularity of Non-Tumorous Hepatic Parenchyma in Patients with Hepatocellular Carcinoma: Potential Pitfalls in Tumor Response Evaluation on Multiphase Computed Tomography , 2014, PloS one.
[9] B. El-Rayes,et al. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. , 2014, Journal of vascular and interventional radiology : JVIR.
[10] M. Abecassis,et al. Radiological‐pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib , 2013, Hepatology.
[11] A. Shuster,et al. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular c , 2013, Journal of vascular and interventional radiology : JVIR.
[12] A. Kramar,et al. Image-based response assessment of liver metastases following stereotactic body radiotherapy with respiratory tracking , 2013, Radiation Oncology.
[13] H. Geinitz,et al. Radiotherapy in marginal zone lymphoma , 2013, Radiation oncology.
[14] B. Kavanagh,et al. Normal liver tissue density dose response in patients treated with stereotactic body radiation therapy for liver metastases. , 2012, International journal of radiation oncology, biology, physics.
[15] Michael L Maitland,et al. RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point. , 2012, Cancer research.
[16] S. Perkins,et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma , 2012, Cancer.
[17] P. Okunieff,et al. An international survey on liver metastases radiotherapy , 2012, Acta oncologica.
[18] Jacob D. Jaffe,et al. Abstract 1: Oncogenic extracellular domain mutations of ERBB2 in cancer , 2012 .
[19] Michael Lock,et al. Radiotherapy for liver metastases: a review of evidence. , 2012, International journal of radiation oncology, biology, physics.
[20] Y. Rolland,et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma , 2012, Cancer.
[21] Tim Meyer,et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. , 2011, Journal of hepatology.
[22] Katarzyna J Macura,et al. Principles and applications of diffusion-weighted imaging in cancer detection, staging, and treatment follow-up. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.
[23] James Ze Wang,et al. Imaging changes after stereotactic body radiation therapy for lung and liver tumors , 2011, Expert review of anticancer therapy.
[24] A. Jemal,et al. Global Cancer Statistics , 2011 .
[25] E. Kunieda,et al. CT evaluations of focal liver reactions following stereotactic body radiotherapy for small hepatocellular carcinoma with cirrhosis: relationship between imaging appearance and baseline liver function. , 2010, The British journal of radiology.
[26] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[27] M. Abecassis,et al. Radiologic–pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium‐90 microspheres , 2009, Hepatology.
[28] M. McCarter,et al. Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. , 2009, International journal of radiation oncology, biology, physics.
[29] L. Gaspar,et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Jordi Rimola,et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma , 2009, Cancer.
[31] W. Franklin,et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[33] G. van Kaick,et al. Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. , 2003, International journal of radiation oncology, biology, physics.
[34] L Pagliaro,et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.
[35] S. Chiou,et al. The triple-phase CT image appearance of post-irradiated livers. , 2001, Acta radiologica.
[36] S. Sourbron,et al. Diffusion and perfusion MRI: basic physics. , 2001, European journal of radiology.
[37] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[38] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[39] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.